LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

Search

Novocure Ltd

Suletud

SektorTervishoid

17.78 1.2

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

17.65

Max

18.04

Põhinäitajad

By Trading Economics

Sissetulek

-47M

-71M

Müük

-295K

174M

Aktsiakasum

-0.62

Kasumimarginaal

-40.871

Töötajad

1,605

EBITDA

-29M

-63M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+46.23% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

23. juuli 2026

Turustatistika

By TradingEconomics

Turukapital

506M

2B

Eelmine avamishind

16.58

Eelmine sulgemishind

17.78

Uudiste sentiment

By Acuity

50%

50%

146 / 342 Pingereas Healthcare

Novocure Ltd Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Ettevõttest Novocure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
help-icon Live chat